Padrão de glicose em mulheres inférteis que recebem reprodução assistida usando monitoramento contínuo de glicose
Padrão de glicose em mulheres inférteis que recebem reprodução assistida: um estudo prospectivo usando o monitoramento contínuo de glicose
No studies have been seen on glucose variation during medication for assisted reproduction. The aim of this study is to continuously observe glucose variation during assisted reproduction treatment using continuous glucose monitoring (CGM), and to further explore whether glucose variation will affect the outcomes related to assisted reproduction.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Infertility is a growing global health concern and affects approximately 20% of couples of reproductive age. As a result, the use of assisted reproductive technologies (ART) is becoming more prevalent. This study could serve as a basis for the interpretation of glucose levels with respect to these people undergoing ART regimen. Moreover, the success rate of ART still needs to be further improved. Key challenges include optimizing the hormonal components of ART regimens and determining the ideal treatment duration. This study might provide insights into the potential benefits of monitoring glucose levels at specific points during ART cycles (which is not usually performed in routine practice) and help clinicians tailor ART regimen to minimize glucose variation, ultimately improving clinical pregnancy and live birth rates. Additionally, the findings might support integrating CGM into the clinical practice of ART, enhancing individualized patient care.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200233
- Shanghai Sixth People's Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Informed consent and voluntary participation in this study;
- Age ≥ 18 years and ≤40 years old;
- Infertile patients who will undergo their first or second cycle of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) at the study center;
- The chosen ovulation promotion regimens is the GnRH antagonist regimen/progesterone-promoting ovulation under hyperprogesterone state (PPOS) regimen.
Exclusion Criteria:
- Recent infections (excluding viral infections of the reproductive system such as HPV);
- Recent glucocorticoid treatment or chemotherapy;
- Clinical conditions affecting the outcome of assisted reproduction, including repeated implantation failure, recurrent spontaneous abortion, history of unilateral oophorectomy, uterine malformations, and parental karyotype abnormalities;
- Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: wearing continuous glucose monitorings
Patients will wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA) to ensure continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation. |
Each patient will participate in the group only once and wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA), which record glucose readings for up to 14 days. Following the initial consultation and before initiating the ovulation induction protocol, the first CGM sensor will be placed to collect baseline data. Upon entering the ovulation induction cycle, patients will return to the hospital on the 2nd or 3rd day of menstruation, at which point the first CGM sensor will be removed, and the second sensor will be applied. This second sensor will be removed after 14 days. In summary, this protocol ensures continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean sensor glucose (MSG)
Prazo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Mean of daily continuous 24-h blood glucose |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
time in tight range(3.9~7.8mmol/L, %)
Prazo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Percentage of time within glucose level of 3.9-7.8 mmol/L (70-140 mg/dL) measured by CGM |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Time below range (<3.9mmol/L, %)
Prazo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Percentage of time below glucose level of 3.9 mmol/L (70 mg/dL) measured by CGM. |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Time above range (>7.8mmol/L, %)
Prazo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Percentage of time above glucose level of 7.8 mmol/L (140 mg/dL) measured by CGM |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Coefficient of variation (CV)
Prazo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Standard deviation divided by mean glucose level measured by CGM |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Standard deviation (SD)
Prazo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Standard deviation of blood glucose measurements during CGM |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of oocytes retrieved
Prazo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
The number of oocytes obtained under ultrasound guidance |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Oocyte retrieval rate
Prazo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Oocyte Retrieval Rate = Number of Oocytes Retrieved / Number of Follicles |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Number of MII oocytes
Prazo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
The number of metaphase II oocytes that have nuclear maturity at the time of injection |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Rate of MII oocytes
Prazo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
the proportion of oocytes that have nuclear maturity at the time of injection |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Rate of high-quality embryos
Prazo: Through study completion (during assisted reproductive treatment period,about 2 months)
|
the proportion of Day 2 and Day 3 embryos with high score or grade |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Biochemical pregnancy rate
Prazo: Through study completion (during assisted reproductive treatment period,about 6 months)
|
The proportion of pregnancies confirmed by the detection of hCG in serum or urine, but without ultrasound confirmation of a gestational sac or fetal heartbeat. |
Through study completion (during assisted reproductive treatment period,about 6 months)
|
|
Clinical pregnancy rate
Prazo: Through study completion (during assisted reproductive treatment period,about 6 months)
|
The proportion of pregnancies confirmed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy |
Through study completion (during assisted reproductive treatment period,about 6 months)
|
|
Miscarriage rate
Prazo: Through study completion, about 1 year
|
The proportion of pregnancies that end spontaneously before 28 weeks of gestation after confirmation of clinical pregnancy |
Through study completion, about 1 year
|
|
Live Birth Rate
Prazo: Through study completion, 18 months
|
The proportion of successful deliveries resulting in a live-born infant. |
Through study completion, 18 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 20250303
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .